Platelet Activating Factor Stability in Urine
1 other identifier
observational
16
1 country
1
Brief Summary
The investigator's hypothesis is that smoking induces inflammation in the bladder wall. This may predispose to the development of Interstitial cystitis(IC) / bladder pain syndrome(BPS). Previous research has linked one the Platelet Activating Factor - PAF to interstitial cystitis. The investigators will study a limited number of patients to determine whether PAF is stable in urine and whether special precautions (for example - immediate freezing in liquid nitrogen) is necessary for accurate measurement of PAF in the urine. Patients who are presenting for an office visit will be asked to donate at least 50 ml of urine. A separate group of patients who are scheduled for surgery, are also being asked to donate around 25 ml of urine during surgery. No patient data other than group assignment, whether they smoke or if they have or not have interstitial cystitis will be recorded.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 18, 2017
CompletedStudy Start
First participant enrolled
January 27, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2017
CompletedFirst Posted
Study publicly available on registry
April 6, 2017
CompletedJuly 18, 2018
July 1, 2018
1 month
January 18, 2017
July 17, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
PAF production
elicits changes in the bladder wall that can predispose to IC/BPS. In this aim, the investigators will determine whether urine PAF is stable at room temperature, or whether special precautions (e.g. freezing or use of PAF-AH inhibitors) are needed for accurate PAF measurements in urine samples.
1 hour
Study Arms (2)
Office
Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature. The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer.
Surgery
A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
Interventions
This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
Eligibility Criteria
Adult females with r without IC
You may qualify if:
- Patient presenting for routine care in the UroGynecology division or
- Patient undergoing gynecologic or urogynecologic surgery exceeding 60 minute operating time.
You may not qualify if:
- Age less than 18 or more than 80
- Unable to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
St. Mary's Health Center
St Louis, Missouri, 63117, United States
Biospecimen
This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eugen C Campian, MD
St. Louis University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
January 18, 2017
First Posted
April 6, 2017
Study Start
January 27, 2017
Primary Completion
February 28, 2017
Study Completion
February 28, 2017
Last Updated
July 18, 2018
Record last verified: 2018-07
Data Sharing
- IPD Sharing
- Will not share